- Report
- January 2024
- 200 Pages
Global
From €4808EUR$5,000USD£4,124GBP
- Report
- April 2024
- 137 Pages
Global
From €3749EUR$3,899USD£3,216GBP
- Drug Pipelines
- April 2024
- 50 Pages
Global
From €1442EUR$1,500USD£1,237GBP
- Drug Pipelines
- October 2020
- 89 Pages
Global
From €1923EUR$2,000USD£1,650GBP
- Report
- January 2021
- 142 Pages
China, Global
From €3000EUR$3,342USD£2,664GBP
- Report
- July 2022
- 63 Pages
Global
From €1923EUR$2,000USD£1,650GBP
- Book
- January 2010
- 616 Pages
- Book
- March 2015
- 512 Pages
Ranolazine is a cardiovascular drug used to treat chronic angina. It works by increasing the amount of blood and oxygen that reaches the heart, reducing the amount of energy the heart needs to pump blood. It is also used to reduce the risk of recurrent chest pain in people with chronic angina. Ranolazine is available in both immediate-release and extended-release formulations.
Ranolazine is a relatively new drug, and its use is still being studied. It is generally well-tolerated, with few side effects. Common side effects include headache, dizziness, nausea, and constipation. It is not recommended for people with certain medical conditions, such as liver or kidney disease.
Ranolazine is marketed by several pharmaceutical companies, including GlaxoSmithKline, Sanofi, and Pfizer. It is also available as a generic drug. Generic versions of ranolazine are typically less expensive than brand-name versions. Show Less Read more
